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Bacteroides fragilis is a bacterium that resides in the normal human gastro-intestinal tract;
however, it is also the most commonly isolated Gram-negative obligate anaerobe from human
clinical infections, such as intra-abdominal abscesses, and the most common cause of anaerobic
bacteraemia. Abscess formation is important in bacterial containment, limiting dissemination of
infection and bacteraemia. In this study, we investigated B. fragilis binding and degradation of
human fibrinogen, the major structural component involved in fibrin abscess formation. We have
shown that B. fragilis NCTC9343 binds human fibrinogen. A putative Bacteroides fragilis
fibrinogen-binding protein, designated BF-FBP, identified in the genome sequence of
NCTC9343, was cloned and expressed in Escherichia coli. The purified recombinant BF-FBP
bound primarily to the human fibrinogen Bb-chain. In addition, we have identified fibrinogenolytic
activity in B. fragilis exponential phase culture supernatants, associated with fibrinogenolytic
metalloproteases in NCTC9343 and 638R, and cysteine protease activity in YCH46. All nine
clinical isolates of B. fragilis examined degraded human fibrinogen; with eight isolates, initial Aa-
chain degradation was observed, with varying Bb-chain and c-chain degradation. With one blood
culture isolate, Bb-chain and c-chain degradation occurred first, followed by subsequent Aa-chain
degradation. Our data raise the possibility that the fibrinogen-binding protein of B. fragilis, along
with a variety of fibrinogenolytic proteases, may be an important virulence factor that facilitates
dissemination of infection via reduction or inhibition of abscess formation.
INTRODUCTION
Bacteroides fragilis is the Gram-negative obligate anaerobe
of the normal human intestinal microbiota most frequently
isolated from opportunistic infections (Patrick, 2002;
Patrick & Duerden, 2006). These include peritonitis,
soft tissue abscesses and bacteraemia, with an estimated
mortality rate of 19% (Patrick et al., 1995; Redondo et al.,
1995). During peritonitis, intra-abdominal abscesses com-
posed primarily of a thick fibrin wall are formed from the
conversion of fibrinogen, a key structural component of
the blood coagulation system, to fibrin. Human fibrinogen
is a 340 kDa glycoprotein, composed of three pairs of non-
identical polypeptide chains: the Aa-chain (610 amino
acids, ~67 kDa), the Bb-chain (461 amino acids, ~55 kDa)
and the c-chain (411 amino acids, ~48 kDa) (Henschen
et al., 1983), bound together by 29 disulphide bridges. A
and B denote the N-terminal peptides that are cleaved by
thrombin from the Aa and Bb chains when fibrin is formed
(Weisel et al., 1985; Weisel, 2005). Bacteria, in the range of
107–109 ml21, in addition to white blood cells, tissue debris
and inflammatory exudates, can be sequestered within an
abscess (Tally & Ho, 1987). Inhibition of formation and
abscess rupture are likely to be important for the
dissemination of infection and bacteraemia. Pathogenic
factors involved in B. fragilis dissemination from the initial
site of infection have yet to be identified conclusively, but
interference with blood clotting proteins may be particu-
larly important.
Several bacterial cell-surface adhesin proteins capable of
binding to human fibrinogen have been linked to virulence
(Patti et al., 1994). These include Staphylococcus aureus
Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
LRR, leucine-rich repeat region; TVC, total viable count.
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proteins FnbpA (fibronectin-binding protein A) (Wann
et al., 2000) and clumping factor A (ClfA), which bind to
the C terminus of the fibrinogen c-chain. Tannerella
forsythia, a Gram-negative bacterium associated with
advanced and recurrent human periodontitis, expresses
an outer membrane surface protein, BspA, associated with
fibrinogen binding (Sharma et al., 1998; Inagaki et al.,
2006; Honma et al., 2001). B. fragilis has been shown to
bind to the extracellular components, fibronectin, collagen,
vitronectin (Nagy et al., 1994; Szoke et al., 1996) and
laminin (Eiring et al., 1995). ELISA analyses have shown
that intact B. fragilis BE1 cells are capable of binding
plasminogen in a dose-dependent manner and plasmino-
gen outer membrane proteins have been described
(Ferreira Ede et al., 2009; Sijbrandi et al., 2005).
In addition to fibrinogen-binding proteins, putative
fibrinogenolytic virulence factors have also been identified
in pathogenic Gram-positive bacteria (e.g. Matsuka et al.,
1999) and in Gram-negative bacteria including anaerobes
[e.g. the Arg-gingipains (RgpA and RgpB) and the Lys-
gingipain Kgp/PrtP of the periodontitis-associated bac-
terium Porphyromonas gingivalis (Barkocy-Gallagher et al.,
1999; Lantz et al., 1991)]. The release of extracellular
enzymes from Bacteroides spp. with the potential to
degrade components of the host has been long recognized
(reviewed by Patrick, 2002). Enzymic activity associated
with copious amounts of single membrane-bound outer
membrane vesicles produced by B. fragilis has also been
described (Patrick et al., 1996; Domingues et al., 1997).
Chen et al. (1995) have demonstrated the fibrinogenolytic
activity of crude B. fragilis cellular extracts and described a
putative 100 kDa monomeric serine-thiol-like fibrinogen-
olytic protease from B. fragilis YCH46, capable of
hydrolysing the substrates azocasein, casein, gelatin, azocoll
and fibrinogen, but unable to degrade BSA, ovalbumin,
fibrin, fibronectin, immunoglobulins, transferrin, hae-
moglobin and collagen types I, III and IV. Whether this
activity related to extracellular or intracellular enzymes was
not resolved. The secreted 20 kDa zinc metalloprotease
enterotoxin, which is associated with acute diarrhoeal
disease in humans and animals (Myers et al., 1984; Myers
& Shoop, 1987; Border et al., 1985), is also reported to have
fibrinogenolytic activity. The role of B. fragilis enterotoxin
is still unclear, however, as the enterotoxin gene has only
been detected in 18% of B. fragilis clinical isolates from
Poland, the UK, Holland and France (Luczak et al., 2001).
There are reports, however, that the enterotoxin gene is
present more frequently in bacteraemia isolates than in
non-blood isolates (Claros et al., 2006).
We now present evidence that B. fragilis is capable of
binding human fibrinogen, an interaction which may be
mediated via a novel fibrinogen-binding putative outer
surface protein, Bacteroides fragilis-fibrinogen binding
protein, which we designate BF-FBP. We also demonstrate
exponential phase proteolysis of fibrinogen by B. fragilis
extracellular proteases not related to the B. fragilis
enterotoxin.
METHODS
Bacterial strains and culture conditions. Isolates studied
included: B. fragilis National Collection of Type Cultures (NCTC)
9343, obtained from the NCTC, London, UK; B. fragilis 638R, a
spontaneous rifampicin-resistant mutant of strain 638 (Privitera
et al., 1979), isolated from an abdominal abscess and kindly gifted by
C. J. Smith, University of East Carolina, USA; B. fragilis YCH46, a
bacteraemia isolate from Yamaguchi Prefecture, Japan, was kindly
gifted by T. Kuwahara, University of Tokushima, Japan; and B. fragilis
SP1, SP2, DK9, LS98, LS66 and LS27, clinical isolates recovered from
patients in Northern Ireland. Escherichia coli DH5a (Invitrogen) was
used for standard cloning protocols. B. fragilis was cultured in either
supplemented brain heart infusion (BHI-S) or defined medium (DM)
broth (Van Tassell & Wilkins, 1978). B. fragilis was cultured in a
MACS MG-1000 anaerobic workstation (Don Whitley) at 37 uC in an
atmosphere of 80% nitrogen, 10% carbon dioxide and 10%
hydrogen. E. coli was cultured using BHI and Luria–Bertani (LB)
medium at 37 uC.
B. fragilis fibrinogen-binding assay. Fibrinogen binding by B.
fragilis strain NCTC9343 was investigated by immunofluorescence
microscopy using B. fragilis cells grown to late-exponential phase in
BHI-S broth. Cells were washed in sterile PBS by centrifugation at
1610 g for 20 min (63) at room temperature, resuspended to OD600
0.3, applied to Teflon-coated multiwell slides (30 ml; ICN
Biomedicals), air-dried and fixed in 100% methanol at 220 uC for
20 min. Duplicate slides were then incubated for 2 and 16 h at 37 uC
with the following concentrations of human fibrinogen in ultrapure
water: 30 ml of 25, 50, 75, 100, 500, and 1000 mg ml21. Slides were
then washed in sterile PBS for 20 min. For blocking experiments,
washed bacteria were pre-incubated with 100 mg human fibrino-
gen ml21 and 1 mg human fibrinogen ml21 at 37 uC for 2 and 48 h,
respectively, washed by centrifugation at 1610 g for 10 min (three
times) in sterile PBS and resuspended (OD600 0.3), and 30 ml was
fixed to multiwell slides as described above. Slides prepared as
described above were then incubated with goat anti-human
fibrinogen polyclonal antiserum (30 ml of 1 : 3000 dilution, Sigma)
at 37 uC for 1 h, washed for 20 min in PBS and then incubated for
1 h at 37 uC with FITC-conjugated rabbit anti-goat IgG antibody
whole molecule (30 ml of 1 : 100 dilution, Sigma) containing 0.2% (v/
v) Evans Blue counter stain. Slides were washed and mounted in a
glycerol–PBS anti-bleaching mounting fluid (Citifluor, Agar
Scientific) and examined at 61000 magnification (Leitz Ortholux
fluorescence microscope). Images were captured using a Nikon DMX
1200 digital camera and Lucia G/F software.
Recombinant BF1705 (rBF-FB) protein expression and puri-
fication. The mature BF1705 coding sequence (with signal sequence
and prokaryotic membrane lipoprotein lipid attachment sites
truncated) was amplified from B. fragilis NCTC9343 genomic DNA
using the forward primer 59-CAGGATCATATGAAAGACTCTCC-
AAACGAATTAA-39 and the reverse primer 59-CAGGATGGATC-
CCAGACCTCAAAGAGCAACG-39, and ligated into the NdeI and
BamHI sites of the pET15b N-terminal His-tag expression vector
(Novagen). E. coli BL21(DE3)-Gold (Stratagene) competent cells were
transformed with the expression vector. The pET15b-BF1705 clone
was confirmed by DNA sequencing. A single transformant was
cultured in 10 ml LB broth containing 100 mg ampicillin ml21,
inoculated into 1 l and incubated at 16 uC for 16 h at 200 r.p.m. in an
orbital incubator (Gallenkamp). Recombinant protein was purified by
affinity column chromatography using nickel nitrilotriacetic acid (Ni-
NTA) resin (Qiagen) according to the manufacturer’s instructions,
flash-frozen and stored at 280 uC.
Protein dot-blot assays and far-Western analysis. rBF-FB
purified protein was dialysed against sodium bicarbonate buffer
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(50 mM NaHCO3, pH 8.5) and labelled with N-hydroxysuccinimide
(NHS)-biotin (Sigma). For dot-blot overlay assays, twofold serial
dilutions consisting of 4.0 mg, 2.0 mg, 1.0 mg, 0.5 mg, 0.25 mg,
0.125 mg, 62.5 ng, 31.2 ng and 0 (negative control) plasminogen-free
human fibrinogen, each mixed with 4 mg BSA, were blotted onto
nitrocellulose membranes (Hybond-C Extra, 45 mm pore-size,
Amersham Biosciences). To demonstrate binding of rBF-FB to
fibrinogen after SDS-PAGE and blotting (far-Western analysis),
plasminogen-free human fibrinogen was electrophoresed on a 10%
(w/v) SDS-PAGE gel and transferred to a nitrocellulose membrane,
washed and blocked as described above. Both dot and far-Western
blots were incubated with gentle rocking in 10 mg ml21 solutions of
biotinylated BF1705 recombinant protein, washed and then incubated
for 30 min at room temperature with 1 : 500 streptavidin–alkaline
phosphatase conjugate [1 : 500 dilution in TBS (50 mM Tris, 150 mM
NaCl, pH 7.5) containing 0.1% (v/v) Tween-20 (Sigma)]. After
washing, blots were treated with Fast BCIP/NBT substrate (Sigma)
according to the manufacturer’s instructions. The experiment was
repeated on two separate occasions.
Fibrinogen degradation by cell-free supernatants and outer
membrane protein extracts. Late-exponential phase and stationary
phase B. fragilis strains NCTC9343, 638R and YCH46 in BHI-S or
DM broth were harvested at 4 uC by centrifugation at 1610 g for
25 min. After filter-sterilization, supernatants were concentrated
(exponential phase supernatants, 22-fold; stationary phase, 15-fold)
at 4 uC using 10 kDa molecular weight cut-off (MWCO) centrifugal
filters (Amicon Centriplus, Millipore). BHI-S broth and DM broth
were prepared as described above.
Outer membrane protein extracts were prepared using Sarkosyl as
previously described (Patrick & Lutton, 1990). This was repeated to
ensure that all potential contaminating inner membrane proteins
were removed by solubilization. The Sarkosyl-insoluble outer
membrane pellet was washed three times in quarter-strength
Ringer’s solution containing L-cysteine (0.5 mg ml21) and suspended
in outer membrane buffer (50 mM Tris/HCl, pH 7.5).
Plasminogen-free human fibrinogen (Sigma) was dissolved in 350 ml
concentrated B. fragilis supernatant or outer membrane protein
extracts (from ~ 4.06109 c.f.u.) to a concentration of 100 mg ml21.
The samples and the negative controls (fibrinogen at 100 mg ml21 in
concentrated BHI-S broth and outer membrane buffer) were
incubated anaerobically for 48 h at 37 uC. Aliquots were removed
after 0, 24 and 48 h and analysed by SDS-PAGE as described below.
Experiments were repeated at least twice.
SDS-PAGE and immunoblot analysis of in situ fibrinogen
degradation. Pre-reduced BHI-S broth containing 100 mg ml21
plasminogen-free human fibrinogen (Sigma) was inoculated with B.
fragilis strains NCTC9343, 638R, YCH46, DK9, LS66, LS27, SP1, SP2
and LS98. Post-inoculation samples (0.5 ml) were removed at 0, 3, 6,
9, 12, 24, 27, 30, 33 and 48 h and centrifuged at 16 100 g for 5 min at
4 uC, and the supernatants were separated aseptically from the cell
pellet. Replicate total viable counts (TVCs) were determined using the
Miles–Misra drop count method. Sterile BHI-S broth containing
100 mg ml21 plasminogen-free human fibrinogen was incubated and
sampled in parallel. Supernatants were analysed by SDS-PAGE [10%
(w/v) Bistris SDS-polyacrylamide gels (NuPAGE, Invitrogen)] at a
constant voltage of 200 V in MOPS SDS running buffer and stained
with Coomassie Blue. Immunoblotting was carried out using
nitrocellulose (Protran 0.45 mm pore-size, Schleicher & Schuell) at
constant voltage (30 V) for 1 h at room temperature. Blots were
blocked for 1 h at 37 uC in Tris-buffered saline (TBS; 50 mM Tris,
150 mM NaCl, pH 7.5), containing 5% (w/v) dried semi-skimmed
milk (Marvel) and 0.05% (v/v) Tween-20, washed at 37 uC in
TBS containing 0.05% (v/v) Tween-20 (TBST), incubated with a
delipidized goat anti-human fibrinogen polyclonal antiserum
(1/ : 10 000 dilution, Sigma) for 1 h at 37 uC, washed in TBS/Tween
(TBST) and incubated for 1 h at 37 uC with an alkaline phosphatase-
conjugated rabbit anti-goat IgG polyclonal antibody (1 : 20 000
dilution whole molecule, Sigma) and again washed. The detection
substrate was Sigma Fast BCIP/NBT (5-bromo-4-chloro-3-indolyl
phosphate/nitro blue tetrazolium; Sigma). Experiments were repeated
at least twice.
Densitometry analysis of fibrinogen degradation. The freely
available ImageJ software from the National Institutes of Health
(http://rsb.info.nih.gov/ij/index.html) was used to perform densi-
tometry analysis of fibrinogen degradation. Briefly, images were
opened in ImageJ and converted to greyscale (B-bit). Settings were
as follows: background noise was corrected using a rolling ball
radius of 50. Set scale/unit of length was set for pixels. Images were
inverted (hence an increase in SDS-PAGE protein band intensity
results in an increased measured grey value). Bands were then
highlighted using the freehand selection tool in order to eliminate
background or gel artefacts. Measurements of the area selected, the
mean grey value and integrated density (area6mean grey area) in
terms of pixels were calculated. The relative intensities of each
fibrinogen chain after 0 and 24 h incubation detected by SDS-PAGE
were calculated (mean grey value at t50 h/mean grey value at
t524 h).
Fibrinogen zymography. Concentrated supernatants or outer
membrane protein extracts as described above were prepared in a
non-reducing treatment buffer and separated on 10% (w/v) SDS-
PAGE gels containing 0.1% (w/v) plasminogen-free human
fibrinogen (Sigma), for 1.5 h at 4 uC and a constant 125 V with a
Tris-glycine running buffer [0.025 M Tris base, 0.192 M glycine,
0.1% (w/v) SDS, pH 8.3] as previously described (Patrick et al.,
2009). Proteinases were renatured by washing twice in 2.5% Triton
X-100 (Sigma), followed by two washes in 50 mM Tris/HCl, pH 7.5,
containing 2.5% (v/v) Triton X-100 (Sigma) and one wash in
50 mM Tris/HCl, pH 7.5, for 15 min at room temperature. Gels
were then incubated for 48 h at 37 uC in a serine protease activation
buffer (50 mM Tris/HCl, pH 8.2, 150 mM NaCl, 5 mM CaCl2), a
metalloprotease activation buffer [50 mM Tris/HCl, pH 7.6,
200 mM NaCl, 5 mM CaCl2, 1 mM ZnCl2, 0.02% (v/v) Brij-35
(polyoxyethyleneglycol dodecyl ether) (Sigma)] or a cysteine
protease activation buffer [50 mM Tris/HCl, pH 6.4 or 7.5,
150 mM NaCl, 10 mM DTT (Sigma)/50 mM L-cysteine (Sigma)]
(Barkocy-Gallagher et al., 1999; Lantz et al., 1991). Zones of lysis
were detected by staining the gel for 2 h at room temperature [25%
(v/v) 2-propanol, 10% (v/v) acetic acid, 64.9% (v/v) ultrapure
water and 0.1% (w/v) Coomassie brilliant blue R-250 (BDH)] and
destained for 16–24 h at room temperature [25% (v/v) 2-propanol,
10% (v/v) acetic acid, 65% (v/v) H2O] until optimum proteolytic
band intensity, observed as clear bands against a dark-blue
background, was achieved. For inhibitor studies, exponential phase
supernatants from B. fragilis NCTC9343 and 638R grown in BHI-S
broth (concentrated 33-fold) were incubated for 60 min at 37 uC in
the presence or absence of 10 mM EDTA or 10 mM PMSF.
The zymogram activation step was also carried out in the presence
or absence of 10 mM EDTA. Experiments were repeated three
times.
MS. His-tagged purified recombinant protein was loaded onto a
Novex 10% (w/v) Tris-glycine polyacrylamide gel (Invitrogen) and
electrophoresed at a constant voltage of 200 V for 1.75 h at 4 uC in
16 Tris-glycine SDS running buffer. Following electrophoresis, the
gel was stained with Gelcode blue staining reagent (Pierce) without
fixing according to the manufacturer’s instructions. B. fragilis
NCTC9343 and 638R were grown to late exponential phase in DM
broth. Supernatant was concentrated 300-fold and separated by SDS-
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PAGE as described above. Resolved protein bands were excised and
prepared for MS by trypsin digestion according to the method of
Aitken & Learmonth (2002).
Samples were subjected to MS analysis using a Voyager DE STR
MALDI-TOF mass spectrometer (Applied Biosystems). The peptide
mass fingerprint spectra for each protein and subsequent protein
identification were obtained using the MASCOT database (Matrix
Science).
RESULTS
Analysis of human fibrinogen binding by
B. fragilis
The interaction of B. fragilis with human fibrinogen was
determined by incubating the bacterium with fibrinogen
followed by labelling with an anti-human fibrinogen
primary antibody and immunofluorescence microscopy.
B. fragilis bound human fibrinogen, as indicated by anti-
human fibrinogen antibody labelling of the bacterial cell
surface (Fig. 1). Results were similar after incubation with
human fibrinogen for either 2 or 24 h, suggesting that
fibrinogen adhesion to the bacterial cell approaches
saturation levels within 2 h of exposure. Non-specific
binding was not evident, as immunofluorescent labelling of
B. fragilis was not detected in the absence of fibrinogen
(data not shown). This indicates that B. fragilis NCTC9343
is capable of interacting with human fibrinogen via one or
more surface components. When B. fragilis NCTC9343
cells are pre-incubated with higher concentrations of
human fibrinogen (1 mg ml21) aggregates are formed
(Fig. 1c).
Fig. 1. Immunofluorescence micrographs of slide-fixed B. fragilis NCTC9343 incubated with (a) 0.1 mg human fibrinogen ml”1
for 2 h or (b) 0.1 mg human fibrinogen ml”1 for 24 h, and (c) B. fragilis NCTC9343 incubated with 1 mg human fibrinogen ml”1
for 2 h prior to slide fixation. Slides were reacted with FITC-conjugated anti-human fibrinogen polyclonal antiserum and
counterstained with Evans Blue. Note the clumping phenotype when bacteria were pre-incubated with fibrinogen.
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Identification, purification and functional
characterization of a novel B. fragilis fibrinogen-
binding protein
A putative 57 kDa outer membrane lipoprotein, encoded
by BF1705, was identified in the genome sequence of strain
NCTC9343 (Cerdeno-Tarraga et al., 2005) as a potential
fibrinogen-binding protein. Sequence analysis predicted
that the protein contains a signal sequence and a
membrane lipoprotein lipid attachment site, indicating
that the molecule may be cell-surface-associated. The
presence of two leucine-rich repeat regions (LRRs) in the
sequence indicates probable protein–protein interactions
(Kobe & Deisenhofer, 1994). In addition, the protein was
predicted to be similar to the LRR-containing surface
antigen BspA of Tannerella forsythia, which binds human
fibrinogen (Sharma et al., 1998). The mature 54 kDa B.
fragilis protein, designated Bacteroides fragilis-fibrinogen
binding protein (BF-FB), was purified to greater than 95%
purity (Fig. 2a); identity was confirmed by trypsin
digestion and MS analysis. Binding of the recombinant
BF-FB (rBF-FB) to human fibrinogen was examined by
protein dot-blotting/overlay. The protein bound human
fibrinogen in a dose-dependent manner, but failed to bind
BSA (Fig. 2b). Binding of biotinylated rBF-FB to human
fibrinogen after SDS-PAGE and blotting (far-Western
analysis) revealed that the B. fragilis protein interacted
strongly with the Bb-chain of fibrinogen and weakly with
the Aa- and c-chains (Fig. 2c).
Fig. 2. Fibrinogen-binding potential of the B. fragilis NCTC9343 rBF-FBP. (a) GelCode Blue-stained SDS-PAGE gel of
purified His-tagged rBF-FBP. (b) Dot-blot analysis of rBF-FBP, demonstrating binding to human fibrinogen. Human fibrinogen
dot blot (twofold dilution; 4.0, 2.0, 1.0, 0.5, 0.25, 0.125, 0.0625, 0.03125 and 0 mg fibrinogen), reacted with biotinylated His-
tagged rBF-FB protein, native (non-biotinylated) rBF-FB protein, or protein buffer only and streptavidin–alkaline phosphatase.
The results are representative of two separate experiments. (c) Immunoblots to detect binding of the biotinylated His-tagged
rBF-FB protein to the Aa-, Bb- and/or c-chains of human fibrinogen. Blots were reacted with goat anti-human fibrinogen
polyclonal antibody and rabbit anti-goat IgG (whole molecule) alkaline phosphatase conjugate (WB) and biotinylated rBF-FB
protein followed by streptavidin–alkaline phosphatase (FWB).
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Fibrinogenolysis activity is associated with
supernatants from B. fragilis broth culture
Initial fibrinogen Aa-chain hydrolysis was observed with
concentrated exponential phase supernatants from the
enterotoxin-negative B. fragilis strains NCTC9343, 638R
and YCH46 (Fig. 3a), confirming that all three express
non-cell-associated proteases during exponential phase
capable of degrading human fibrinogen. SDS-PAGE
analysis of fibrinogen degradation by outer membrane
protein extracts from strains NCTC9343 and YCH46
reproducibly failed to detect hydrolysis of the fibrinogen
chains (data not shown); however, partial hydrolysis of the
Aa-chain by the outer membrane protein extracts of strain
638R was observed following 24 h incubation (Fig. 3b).
This was confirmed by measuring SDS-PAGE band
intensity using ImageJ software. The relative percentage
band intensity of the fibrinogen chains at t524 h com-
pared with t50 h for the Aa-chain was 50.4%, for the
Bb-chain 92.0% and for the c-chain 85.5%
Supernatants from exponential phase cultures of B. fragilis
strains NCTC9343, 638R and YCH46 were studied further
in fibrinogen zymography experiments. Fibrinogenolytic
activity (at ~45 and 50 kDa) was detected in the expo-
nential phase supernatants from BHI-S-grown cultures
(Fig. 4a), and also in stationary phase supernatants (not
illustrated) from strains NCTC9343 and 638R following
protein refolding and activation in serine protease and
metalloprotease activation buffers. Activity at the same
molecular mass was also evident in DM-grown culture
supernatants (not illustrated). Inhibition of this activity
was observed after pre-incubation with the metalloprotease
inhibitor, EDTA, but not the serine protease inhibitor
PMSF (Fig. 4b). Activity was compared with a negative
control sample of concentrated media broth and positive
control samples of supernatants lacking inhibitor. These
results suggest that the two exponential phase fibrinogen-
olytic proteases of NCTC9343 and 638R belong to the
metalloprotease catalytic type of enzyme. In contrast, only
faint fibrinogenolytic activity (~45 kDa) was detected in
cysteine protease activation buffer with strainYCH46 (not
illustrated).
MS analyses of proteins in the 35–60 kDa molecular mass
range, obtained by excision of Gelcode blue-stained SDS-
PAGE gels of 100-fold concentrated supernatants from B.
fragilis mid-exponential phase cultures grown in defined
medium, did not, however, reveal any proteases predicted
by the complete genome sequence annotation. Predicted B.
fragilis proteins that were detected included putative RagB
(Hanley et al., 1999) homologues encoded by BF2196,
BF0595 and BF0597. These have predicted signal sequences
with lipoprotein lipid attachment sites and are paired with
putative ragA genes that contain TonB-dependent receptor
motifs. In Porphyromonas gingivalis, RagA is an immuno-
dominant surface antigen. BF0595 and 0597 are part of a
complex invertible region (IRCC) shufflon, active in the
shotgun sequence of NCTC9343 and containing four ragA/
B-like pairs of genes each capable of shuffling from silent
loci into an expression locus as a result of DNA inversion
(Cerdeno-Tarraga et al., 2005). BF0991 encodes a hypo-
thetical protein located in a cluster of four genes, all with
predicted signal peptides, downstream of a putative
transcriptional regulator; these genes include a putative
outer membrane protein and a gene with similarity to a
membrane-associated haemolysin transporter, suggesting
that this region is involved in export. In addition
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
identified. Although recognized as a classical cytoplasmic
housekeeping enzyme, GAPDH has also been reported to
Fig. 3. Comparison of the fibrinogenolytic potential of concen-
trated exponential phase supernatants and outer membrane
protein extracts of B. fragilis. (a) SDS-PAGE gel analysis of
fibrinogen degradation by B. fragilis NCTC9343, 638R and
YCH46 exponential phase supernatants over 48 h. M, molecular
mass markers. (b) SDS-PAGE gel analysis of fibrinogen degrada-
tion by B. fragilis 638R outer membrane protein extracts over 24 h.
Lanes are labelled with time points (h); M, molecular mass markers.
The results are representative of two separate experiments.
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be located on the cell surface of, and secreted by,
enterohaemorrhagic and enteropathogenic E. coli (Egea
et al., 2007). The concentrated DM culture supernatant
would have contained outer membrane vesicles which
originate from the outer membrane by budding (Lutton
et al., 1991) and have demonstrable enzymic activity
(Patrick et al., 1996).
Comparison of the fibrinogenolytic potential of B.
fragilis clinical isolates
To determine the relationship between fibrinogenolytic
activity and growth phase, the three fully sequenced strains
(NCTC9343, 638R and YCH46) were compared by the
combination of TVCs, SDS-PAGE and immunoblot
analysis during 48 h growth in BHI-S broth. Fibrinogen
alone was stable in BHI-S during this time period, whereas
partial hydrolysis of the Aa-chain was observed 6–12 h
post-inoculation (late exponential phase) in the three fully
sequenced strains, with complete degradation by 12–24 h
(early to mid stationary phase; Fig. 5, Table 1). Initiation of
Bb-chain hydrolysis by these strains occurred 12–24 h after
incubation (early to mid stationary phase) and was
complete by 33–48 h (late stationary/early death phases;
Fig. 5). Degradation of the fibrinogen c-chain by strains
NCTC9343 and 638R was not as obvious after SDS-PAGE
analysis of the supernatants. The immunoblots, however,
indicated that a noticeable proportion of the c-chain was
hydrolysed by 33 h, and epitopes detected by the anti-
human fibrinogen antiserum were completely degraded by
48 h with NCTC9343 and 638R. TVCs indicated that c-
chain degradation by both these strains commenced dur-
ing late stationary phase. In contrast, with strain YCH46
(Fig. 5c), hydrolysis was observed by 12–24 h post-
inoculation, during early to mid stationary phase. This
suggests that YCH46 expresses proteases additional to or
different from those of the other two strains. Fibrinogen
degradation profiles for a further four abscess and two
bacteraemia B. fragilis clinical isolates (Table 1) revealed
initial degradation of the Aa-chain commencing during the
late exponential growth phase, followed by the stationary
phase cleavage of the Bb-chain and partial, often less
intense, degradation of the c-chain. A different pattern was
observed for bacteraemia isolate SP2, which degraded the
Bb- and c-chains prior to the Aa-chain degradation, and
initiated degradation of all three chains within 6–12 h,
corresponding to the mid–late exponential growth phase
(Fig. 6).
DISCUSSION
This is the first study, to our knowledge, to demonstrate
the binding of human fibrinogen to the surface of B. fragilis
and the identification and purification of BF-FB, a putative
surface lipoprotein encoded by BF1705 of B. fragilis strain
NCTC9343 (Cerdeno-Tarraga et al., 2005), and also
identified in the genomes of strains 638R (S. Patrick
and others, unpublished results) and YCH46 (Kuwahara
et al., 2004). Fibrinogen adhesion to the B. fragilis cell
surface was clearly evident within two hours of exposure, a
property that could be advantageous during infection. This
rapid binding would potentially interfere with fibrinogen
functions, such as abscess formation, and as a result of
bacterial aggregation/clump formation may also confer
resistance to phagocytosis (Kapral, 1966; Dominiecki &
Fig. 4. Fibrinogen zymography of B. fragilis NCTC9343, 638R and YCH46. (a) Exponential phase supernatants (S), outer
membrane extracts (OM) and concentrated BHI-S media broth alone (C) activated in serine protease and metalloprotease
activation buffers. (b) Fibrinogen zymography of B. fragilis NCTC9343 and 638R concentrated exponential phase supernatants
incubated with the protease inhibitors EDTA (10 mM) and PMSF (10 mM). The results are representative of three separate
experiments.
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Fig. 5. Comparison of the fibrinogenolytic
potential of B. fragilis cultures. SDS-PAGE
gel analysis (left-hand panels) and immunoblot
analysis (right-hand panels) of fibrinogen
degradation by B. fragilis NCTC9343 (a),
638R (b) and YCH46 (c) for 0–48 h and
corresponding growth curves at each time
point during 48 h fibrinogen degradation
experiments (mean±SE of six replicate experi-
ments). Immunoblots were reacted with goat
anti-human fibrinogen polyclonal antiserum.
Lanes are labelled with time points (h); M,
molecular mass markers. (d) Negative control.
Note that fibrinogen was stable over 48 h
(negative control), whereas fibrinogen incu-
bated with the three B. fragilis strains was
degraded.
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Weiss, 1999). The genetic conservation of BF-FB suggests
that it is also involved in survival within the gastro-
intestinal tract. Purified recombinant BF-FB binds to
human fibrinogen through interaction predominantly with
the Bb-chain. The 95 kDa cell-surface fibrinogen-binding
protein orthologue BspA of T. forsythia contains 14 LRR
motifs (Sharma et al., 1998), in comparison with BF-FB,
which has only two LRRs. Whether the LRRs are involved
in multimer formation or are directly involved in
fibrinogen binding is unknown, but the reduction in LRR
motifs in B. fragilis clearly does not preclude fibrinogen
binding by the recombinant protein.
NCTC9343, 638R and YCH46 all exhibited non-cell-
associated fibrinogenolytic activity in concentrated super-
natants. As these strains are enterotoxin-negative, this
activity was not associated with enterotoxin. Zymography
revealed metalloprotease activity associated with non-cell-
associated proteins of 45 and 50 kDa in NCTC9343 and
638R, and weaker activity in cysteine activation buffer with
strain YCH46. As YCH46 in culture degraded fibrinogen as
effectively as NCTC9343 and 638R, clearly B. fragilis has
more than one potential mechanism for fibrinogen
degradation. Chen et al. (1995) have reported that a
cellular extract from B. fragilis YCH46 degrades fibrinogen
when examined by SDS-PAGE analysis. Although we also
observed degradation by this strain, we did not identify the
100 kDa serine-thiol-like protease of B. fragilis YCHC46
reported by Chen and colleagues in our supernatants or
our zymography studies; nor was a putative corresponding
cell-surface or secreted 100 kDa serine-thiol-like protease
candidate gene identified by in silico genome analyses. It is
possible that the serine-thiol-like protease purified by Chen
et al. (1995) was intracellular in origin, as only whole-cell
extracts were examined. Examination of these strains and a
further six clinical isolates by culture in fibrinogen-
containing medium showed that, with one exception,
initiation of degradation of the fibrinogen Aa-chain
occurred first during the exponential growth phase,
followed by Bb-chain hydrolysis. Proteolysis was therefore
occurring during active growth of the bacteria and was not
simply an activity resulting from bacterial cell death and
the release of cytoplasmic components. Degradation of the
c-chain was more variable. It remained stable with some
isolates and was not degraded until stationary phase with
others. Interestingly, blood culture isolate SP2 rapidly
degraded fibrinogen Bb- and c-chains. Whether this is
related to an enhanced capability for dissemination and
bacteraemia remains to be determined, as there was no
common pattern for all bacteraemia isolates. These data
demonstrate that different isolates may produce more than
one or different types of fibrinogen-degrading proteases.
Fibrinogen molecules are composed of six polypeptide
chains, two of each of the Aa-, Bb- and c-chains, linked by
disulphide bonds. One of each of the Aa, Bb and c chains
extends outwards to either side of the central E domain
(which contains the N termini), forming two globular
Table 1. Time-course of the initiation of fibrinogen chain
degradation by nine B. fragilis strains as determined by a
combination of SDS-PAGE, immunoblotting and TVC analyses
Isolate Time period to initiation of fibrinogen
degradation (h)
Aa-chain Bb-chain c-Chain
SP2* 6–12 0–6d 0–6d
YCH46*, 638RD 6–12 12–24 12–24
LS98*, DK9D 6–12 12–24 24–48
NCTC9343D 6–12 12–24 30–48
LS27D 12–24 12–24 12–24
SP1* 6–12 6–12 Stable
LS66D 6–12 12–24 Stable
*Blood culture isolate.
DAbscess isolate.
dNote that degradation of fibrinogen Bb- and c-chains was initiated
before that of the Aa-chain.
Fig. 6. Coomassie blue SDS-PAGE gel analysis of fibrinogen
degradation by B. fragilis SP2 over 48 h (top panel) with the
corresponding growth curve at each time point (lower panel). Note
the fibrinogen degradation 0–6 h following exposure of B. fragilis
to fibrinogen and Bb- and c-chain degradation prior to Aa-chain
degradation. The results are representative of a minimum of two
replicate experiments.
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outer D domains. The C termini of the Bb- and c-chains
are located within the globular D domains. In contrast, the
Aa-chains extend outside the globular D domains, back
inwards towards the N termini in the central E domain
(Doolittle, 1984; Weisel et al., 1985; Weisel, 2005). The
difference in the Aa-chain location may therefore account
for its increased predisposition to proteolytic attack by
certain proteases. Interestingly, Pseudomonas aeruginosa
elastase (Komori et al., 2001) and Streptococcus pyogenes
extracellular cysteine protease (Matsuka et al., 1999) both
target the Aa-chain. A reduction or absence of this subunit
alone, even in the presence of normal Bb and c fibrinogen,
is sufficient to adversely affect clot formation in the
condition known as afibrinogenaemia (Neerman-Arbez,
2001). Thus, prevention of clot formation may be a crucial
mechanism by which B. fragilis evades the host abscess-
forming defence mechanism.
MS analysis of proteins in the molecular mass region
corresponding to the detected fibrinogenolytic activity
did not reveal a candidate enzyme containing a signal
sequence. GAPDH was, however, detected. Classical
cytoplasmic housekeeping enzymes such as glycolytic
enzymes, including enolase and GAPDH, have been shown
to be localized to the outer surface of some pathogenic
microbes and have been related to virulence (Pancholi &
Chhatwal, 2003). The presence of putative lipoproteins,
such as RagB homologues, suggests that these are likely to
be associated with outer membrane vesicles, which would
have been present in the broth culture supernatants.
The expression of the fibrinogen-binding protein (BF-FBP)
and fibrinogenolytic proteases by B. fragilis, described
herein, may represent important virulence factors in B.
fragilis, allowing the bacteria to slow down or prevent
abscess formation and promote abscess dissolution, result-
ing in dissemination of infection, and may potentiate the
rapid release of large numbers of B. fragilis into the host
circulation, resulting in bacteraemia.
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